Cipla Toekomstige groei
Future criteriumcontroles 1/6
Cipla zal naar verwachting groeien in winst en omzet met respectievelijk 13.7% en 10.3% per jaar. De winst per aandeel zal naar verwachting groeien met 13.7% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 13.1% zijn.
Belangrijke informatie
13.7%
Groei van de winst
13.71%
Groei van de winst per aandeel
| Pharmaceuticals winstgroei | 16.1% |
| Inkomstengroei | 10.3% |
| Toekomstig rendement op eigen vermogen | 13.13% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 26 May 2026 |
Recente toekomstige groei-updates
Analyseartikel • May 16
Cipla Limited Just Missed EPS By 7.0%: Here's What Analysts Think Will Happen Next
Cipla Limited ( NSE:CIPLA ) missed earnings with its latest annual results, disappointing overly-optimistic...Analyseartikel • Jan 28
Cipla Limited Just Missed EPS By 48%: Here's What Analysts Think Will Happen Next
The analysts might have been a bit too bullish on Cipla Limited ( NSE:CIPLA ), given that the company fell short of...Analyseartikel • Nov 02
Analyst Estimates: Here's What Brokers Think Of Cipla Limited (NSE:CIPLA) After Its Second-Quarter Report
Cipla Limited ( NSE:CIPLA ) just released its latest quarterly results and things are looking bullish. Results were...Recent updates
Narratiefupdate • Jun 05
CIPLA: Fair Outlook As New CEO And Respiratory Portfolio Changes Take Shape
Analysts have raised their price target on Cipla by about ₹30 to ₹1,459.57, citing updated assumptions for revenue growth, profit margins and a slightly lower future P/E multiple, alongside a marginally higher discount rate. What's in the News Cipla launched Ciposcillo, an advanced oscillometer for early detection of respiratory diseases like COPD and asthma.Analyseartikel • May 16
Cipla Limited Just Missed EPS By 7.0%: Here's What Analysts Think Will Happen Next
Cipla Limited ( NSE:CIPLA ) missed earnings with its latest annual results, disappointing overly-optimistic...Narratiefupdate • Apr 27
CIPLA: New CEO, US Respiratory Launch And Biologics Venture Will Steady Outlook
Analysts now place Cipla's fair value at ₹1,429.83, a small move from ₹1,427.58. This reflects refreshed assumptions around revenue growth, profit margin and future P/E expectations.Narratiefupdate • Apr 12
CIPLA: New CEO And Biologics Venture Will Support Stronger Outlook
Cipla's analyst fair value estimate has been adjusted slightly from about ₹1,436.58 to ₹1,427.58, reflecting updated assumptions around revenue growth, profit margins and future P/E expectations according to analysts. What's in the News Cipla plans a board meeting on May 13, 2026, to review standalone and consolidated audited financial results for the quarter and year ended March 31, 2026, and to consider a final dividend for the year, if any (company filing).Narratiefupdate • Mar 27
CIPLA: New CEO And Biologics Venture Will Support Stronger Long Term Outlook
Analysts have trimmed Cipla's implied fair value price target slightly from ₹1,446.31 to ₹1,436.58, reflecting updated views on its revenue growth, profit margin outlook, and future P/E assumptions. What's in the News A board meeting is scheduled for 19 Mar 2026 to consider appointing P R Ramesh, Lead Independent Director, as Vice Chairman, and to take up the planned exit of Independent Director Robert Stewart after completion of his current term, along with other matters (Key Developments).Narratiefupdate • Mar 13
CIPLA: Pfizer Alliance And CEO Transition Will Shape Steady Forward Outlook
Analysts have kept their Cipla price target unchanged at ₹1,446.31, reflecting consistent assumptions on discount rate, revenue growth, profit margin and future P/E in their models. What's in the News Cipla has agreed to a 60:40 joint venture with Kemwell Biopharma in India to develop, obtain licenses for, manufacture, commercialise, import and export biologic products, with scope to license or outsource these activities (company announcement).Narratiefupdate • Feb 27
CIPLA: Pfizer Tie-Up And Leadership Shift Will Shape Balanced Outlook
Analysts have trimmed their price target on Cipla by about ₹10 to reflect slightly softer assumptions around long term revenue growth and profit margins, while keeping the P/E framework broadly unchanged. What's in the News Pfizer India and Cipla entered into a partnership under which Cipla will exclusively market and distribute four Pfizer brands in India, including Corex Dx, Corex LS, Dolonex, Neksium and Dalacin C, while Pfizer continues to manufacture and supply these medicines (Key Developments).Narratiefupdate • Feb 13
CIPLA: Pfizer Partnership And Upcoming Results Will Guide Balanced Future Expectations
Analysts have trimmed their price target for Cipla slightly to ₹1,456 from about ₹1,459, reflecting updated assumptions on discount rate, revenue growth, profit margin and future P/E that are broadly in line with prior views. What's in the News Pfizer India and Cipla entered into a partnership under which Cipla will exclusively market and distribute four Pfizer brands in India, covering Corex Dx and Corex LS cough syrups, Dolonex (NSAID), Neksium (PPI) and Dalacin C (oral antibiotic).Narratiefupdate • Jan 30
CIPLA: Pfizer Alliance And Upcoming Results Will Shape Measured Future Upside Potential
Analysts have revised their fair value estimate for Cipla to ₹1,458.53, down from ₹1,657.58, citing updated assumptions for revenue growth, profit margins and future P/E multiples. What's in the News Cipla has scheduled a board meeting on Jan 23, 2026, at 11:00 Indian Standard Time to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (company filing).Analyseartikel • Jan 28
Cipla Limited Just Missed EPS By 48%: Here's What Analysts Think Will Happen Next
The analysts might have been a bit too bullish on Cipla Limited ( NSE:CIPLA ), given that the company fell short of...Analyseartikel • Jan 17
The Market Doesn't Like What It Sees From Cipla Limited's (NSE:CIPLA) Earnings Yet
With a price-to-earnings (or "P/E") ratio of 20.7x Cipla Limited ( NSE:CIPLA ) may be sending bullish signals at the...Narratiefupdate • Jan 16
CIPLA: Pfizer Partnership And Leadership Transition Will Support Future Upside Potential
Analysts have slightly reduced their fair value estimate for Cipla to ₹1,658 from ₹1,677, citing updated assumptions that combine modestly higher revenue growth expectations with some pressure on profit margins and a marginally adjusted future P/E multiple. What's in the News A board meeting is scheduled on January 23, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Analyseartikel • Dec 29
We Think Cipla (NSE:CIPLA) Can Stay On Top Of Its Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyseartikel • Nov 20
Does Cipla (NSE:CIPLA) Deserve A Spot On Your Watchlist?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analyseartikel • Nov 02
Analyst Estimates: Here's What Brokers Think Of Cipla Limited (NSE:CIPLA) After Its Second-Quarter Report
Cipla Limited ( NSE:CIPLA ) just released its latest quarterly results and things are looking bullish. Results were...Analyseartikel • Sep 24
Cipla Limited's (NSE:CIPLA) Prospects Need A Boost To Lift Shares
With a price-to-earnings (or "P/E") ratio of 22.9x Cipla Limited ( NSE:CIPLA ) may be sending bullish signals at the...Analyseartikel • Sep 06
Cipla (NSE:CIPLA) Seems To Use Debt Quite Sensibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Narratiefupdate • Sep 04
Emerging Markets And Chronic Therapies Will Open New Horizons
With consensus forecasts for both revenue growth (8.4% p.a.) and net profit margin (15.92%) remaining steady, Cipla's Analyst Price Target was left unchanged at ₹1677. What's in the News Cipla is significantly expanding its US manufacturing capacity with an 83,000-square-foot addition at its Fall River, Massachusetts facility, focusing on complex respiratory products, and will utilize advanced technology to enhance production and efficiency.Analyseartikel • Jul 13
Here's Why Cipla (NSE:CIPLA) Has Caught The Eye Of Investors
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Nieuw narratief • Nov 10
Aspirational Inhalation Launches And African Expansion Propel Growth Ambitions
Planned respiratory therapies and product launches could drive increased revenue and enhance the chronic therapy segment's growth.Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 3/31/2029 | 378,943 | 57,759 | 37,701 | 55,901 | 14 |
| 3/31/2028 | 346,374 | 51,196 | 36,108 | 49,851 | 35 |
| 3/31/2027 | 310,811 | 41,864 | 30,077 | 43,810 | 35 |
| 3/31/2026 | 278,278 | 38,792 | 9,048 | 39,400 | N/A |
| 12/31/2025 | 279,672 | 45,464 | N/A | N/A | N/A |
| 9/30/2025 | 279,658 | 54,411 | 27,544 | 42,949 | N/A |
| 6/30/2025 | 274,796 | 53,925 | N/A | N/A | N/A |
| 3/31/2025 | 272,674 | 52,725 | 34,653 | 50,050 | N/A |
| 12/31/2024 | 267,201 | 49,897 | N/A | N/A | N/A |
| 9/30/2024 | 262,642 | 44,751 | 29,520 | 45,008 | N/A |
| 6/30/2024 | 258,922 | 43,035 | N/A | N/A | N/A |
| 3/31/2024 | 255,367 | 41,216 | 27,846 | 41,339 | N/A |
| 12/31/2023 | 251,163 | 37,082 | N/A | N/A | N/A |
| 9/30/2023 | 243,407 | 34,532 | 25,988 | 37,924 | N/A |
| 6/30/2023 | 235,108 | 31,112 | N/A | N/A | N/A |
| 3/31/2023 | 225,593 | 28,019 | 20,736 | 32,377 | N/A |
| 12/31/2022 | 222,187 | 26,383 | N/A | N/A | N/A |
| 9/30/2022 | 218,874 | 25,660 | 20,120 | 29,160 | N/A |
| 6/30/2022 | 216,105 | 24,884 | N/A | N/A | N/A |
| 3/31/2022 | 217,078 | 25,168 | 26,285 | 33,259 | N/A |
| 12/31/2021 | 210,718 | 25,681 | N/A | N/A | N/A |
| 9/30/2021 | 207,616 | 25,876 | 28,362 | 37,113 | N/A |
| 6/30/2021 | 202,801 | 25,417 | N/A | N/A | N/A |
| 3/31/2021 | 191,205 | 24,049 | 29,418 | 37,552 | N/A |
| 12/31/2020 | 188,779 | 22,374 | N/A | N/A | N/A |
| 9/30/2020 | 180,802 | 18,403 | 23,627 | 31,968 | N/A |
| 6/30/2020 | 174,377 | 16,462 | N/A | N/A | N/A |
| 3/31/2020 | 170,805 | 15,465 | 20,684 | 30,685 | N/A |
| 12/31/2019 | 171,206 | 16,678 | N/A | N/A | N/A |
| 9/30/2019 | 167,572 | 16,489 | N/A | 25,720 | N/A |
| 6/30/2019 | 163,733 | 15,546 | N/A | N/A | N/A |
| 3/31/2019 | 163,232 | 15,277 | N/A | 16,911 | N/A |
| 12/31/2018 | 155,224 | 13,391 | N/A | N/A | N/A |
| 9/30/2018 | 154,287 | 14,074 | N/A | N/A | N/A |
| 6/30/2018 | 154,992 | 14,530 | N/A | N/A | N/A |
| 3/31/2018 | 151,053 | 14,105 | N/A | 14,628 | N/A |
| 12/31/2017 | 147,618 | 11,701 | N/A | N/A | N/A |
| 9/30/2017 | 144,951 | 11,444 | N/A | N/A | N/A |
| 6/30/2017 | 141,637 | 10,762 | N/A | N/A | N/A |
| 3/31/2017 | 143,340 | 10,064 | N/A | 23,818 | N/A |
| 12/31/2016 | 142,509 | 11,213 | N/A | N/A | N/A |
| 9/30/2016 | 137,547 | 10,071 | N/A | N/A | N/A |
| 6/30/2016 | 134,335 | 12,219 | N/A | N/A | N/A |
| 3/31/2016 | 135,480 | 13,600 | N/A | 17,408 | N/A |
| 12/31/2015 | 135,044 | 16,847 | N/A | N/A | N/A |
| 9/30/2015 | 131,633 | 16,694 | N/A | N/A | N/A |
| 6/30/2015 | 124,782 | 15,368 | N/A | N/A | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei CIPLA ( 13.7% per jaar) ligt boven de spaarquote ( 6.9% ).
Winst versus markt: De winst van CIPLA ( 13.7% per jaar) zal naar verwachting langzamer groeien dan de markt Indian ( 16.2% per jaar).
Hoge groeiwinsten: De winst van CIPLA zal naar verwachting groeien, maar niet aanzienlijk.
Omzet versus markt: De omzet van CIPLA ( 10.3% per jaar) zal naar verwachting langzamer groeien dan de markt Indian ( 10.8% per jaar).
Hoge groei-inkomsten: De omzet van CIPLA ( 10.3% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen CIPLA zal naar verwachting over 3 jaar laag zijn ( 13.1 %).
Ontdek groeibedrijven
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/06/07 14:33 |
| Aandelenkoers aan het einde van de dag | 2026/06/05 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2026/03/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Cipla Limited wordt gevolgd door 55 analisten. 35 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Gaurav Tinani | Ambit Capital |
| null null | Anand Rathi Shares and Stock Brokers Limited |